Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 650.11K | 959.42K | 615.57K | 816.01K | 696.27K | 702.16K |
| Gross Profit | -691.43K | -924.12K | -1.12M | -1.53M | -1.90M | -397.67K |
| EBITDA | -13.23M | -15.55M | -21.87M | -16.47M | -19.57M | -11.43M |
| Net Income | -29.41M | -29.69M | -22.63M | -17.53M | -20.56M | -13.08M |
Balance Sheet | ||||||
| Total Assets | 55.57M | 21.62M | 8.31M | 13.70M | 26.86M | 33.57M |
| Cash, Cash Equivalents and Short-Term Investments | 50.34M | 15.71M | 831.52K | 5.69M | 18.52M | 25.14M |
| Total Debt | 24.81M | 21.35M | 10.42M | 4.49M | 1.74M | 1.39M |
| Total Liabilities | 32.49M | 29.00M | 17.06M | 6.19M | 4.46M | 4.75M |
| Stockholders Equity | 23.08M | -7.38M | -12.83M | 7.51M | 22.40M | 28.82M |
Cash Flow | ||||||
| Free Cash Flow | -12.27M | -15.65M | -13.06M | -17.06M | -18.11M | -12.97M |
| Operating Cash Flow | -12.12M | -15.57M | -12.98M | -16.82M | -17.49M | -12.23M |
| Investing Cash Flow | -157.60K | -74.98K | -82.78K | -238.86K | -695.30K | -774.03K |
| Financing Cash Flow | 32.21M | 30.33M | 8.21M | 3.94M | 11.59M | 33.02M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$76.80M | ― | -128.19% | ― | -14.25% | -22.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $89.59M | ― | -74.00% | ― | 23.31% | -17.35% | |
45 Neutral | €35.43M | -6.54 | -513.22% | ― | -34.06% | 75.47% | |
44 Neutral | ― | ― | -432.03% | ― | -8.99% | -18.16% | |
43 Neutral | AU$170.03M | -16.13 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$81.13M | ― | -31.98% | ― | 34.20% | -23.90% |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Medical Systems, Inc. has achieved significant milestones in its operations, including the submission of 510(k) approvals for its NorthStar and Vision-MR Diagnostic Catheter with the FDA, and the commercial launch of NorthStar in Europe following CE Mark approval. The company is expanding its clinical trial footprint and driving adoption of its MRI-guided electrophysiology products, with a growing European pipeline and discussions with US hospitals revealing a larger-than-expected installed base of cardiology-controlled MRI scanners. Financially, Imricor reported operating cash outflows of US$4.8 million for Q3 2025, with a cash balance of US$38.3 million and US$7.5 million in short-term investments, as it continues to focus on expanding its market presence and transforming cardiac ablation procedures worldwide.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has presented at the Canaccord Drug & Device Conference, highlighting its vision to expand the use of iCMR technology globally. This strategic move aims to enhance its market positioning by leveraging its unique MRI-compatible products, potentially impacting stakeholders by broadening the adoption of advanced cardiac procedures.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has announced a groundbreaking achievement by performing the world’s first Pulsed Field Ablation (PFA) under real-time MRI guidance in an iCMR lab. This advancement marks a significant milestone in Imricor’s PFA development program, demonstrating the flexibility and adaptability of their platform. The procedure, conducted using the second-generation Vision-MR Ablation Catheter, validates Imricor’s proprietary technology for integrating PFA energy with real-time MRI visualization. This innovation positions Imricor to meet the evolving needs of electrophysiologists globally and underscores the company’s commitment to advancing MRI-guided electrophysiology procedures.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. announced the cessation of 3,750 securities due to the expiry of options or other convertible securities without exercise or conversion as of October 1, 2025. This cessation could impact the company’s financial structure and stakeholder interests, reflecting a strategic adjustment in its capital management.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. announced the issuance of 30,000 unquoted equity securities as part of an employee incentive scheme. This strategic move is likely to strengthen employee engagement and align interests with the company’s growth objectives, potentially enhancing its competitive position in the medical technology sector.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has announced the application for the quotation of 11,250 securities on the ASX, reflecting the company’s ongoing efforts to enhance its market presence and financial flexibility. This move is expected to support Imricor’s strategic initiatives and operations, potentially strengthening its industry positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. announced the application for the quotation of 344,900 new securities on the Australian Securities Exchange (ASX), with an issue date of September 6, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for further development and expansion, reflecting a significant step in its growth trajectory and offering potential implications for investors and stakeholders.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has submitted its Vision-MR Diagnostic Catheter for FDA 510(k) approval, marking a significant step towards expanding its MRI-compatible electrophysiology devices in the U.S. market. This move, along with the recent submission of the NorthStar 3D mapping system, aims to establish a comprehensive, radiation-free platform for cardiac procedures, potentially transforming the industry and enhancing Imricor’s market position.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. announced the release of 242,875 Class A Common Stock from voluntary escrow, effective September 6, 2025. This move is part of the company’s ongoing efforts to manage its securities and may impact its market operations by increasing the liquidity of its shares. The release aligns with the company’s strategic objectives to expand its market presence and enhance shareholder value.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has released its 1H 2025 investor presentation, highlighting its ongoing commitment to expanding the reach of its iCMR technology in cardiac centers globally. The presentation underscores the company’s strategic focus on leveraging its innovative MRI-compatible solutions to enhance cardiac procedures, potentially impacting its market positioning and offering growth opportunities for stakeholders.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has made significant strides in its operations and regulatory achievements, including the submission of a second Premarket Approval Module to the US FDA and receiving CE Mark approval for its second-generation products. The company is advancing its clinical trials, expanding its customer pipeline, and establishing new iCMR labs in Saudi Arabia. Despite a temporary revenue impact due to clinical trial participation, Imricor expects revenue growth as trials conclude and FDA approval is obtained. The company’s strong cash position supports its growth initiatives, positioning it as a transformative player in the rapidly growing electrophysiology market.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. has announced that it will release its financial results for the first half of fiscal year 2025 on August 26, 2025. The company will also host an investor webinar on the same day, featuring presentations from its Chair and CEO, Steve Wedan, and CFO, Jonathon Gut. This announcement is significant as it provides stakeholders with insights into the company’s financial health and strategic direction, potentially impacting investor decisions and market perception.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. highlighted the growing global challenge of cardiac arrhythmias, which are disturbances in heart rhythm that can lead to severe health events like strokes and sudden cardiac death. The company presented at the Canaccord Annual Growth Conference, emphasizing the increasing prevalence of arrhythmias in the U.S., which has doubled since 1990 and is projected to double again by 2030, affecting 4% of the population. This underscores the importance of Imricor’s mission to implement iCMR technology in cardiac centers worldwide, potentially improving patient outcomes and positioning the company as a leader in cardiac care innovation.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems, Inc. reported significant progress in Q2 2025, with notable regulatory achievements including CE mark approvals for its Advantage-MR system and NorthStar mapping system under the new European Medical Device Regulation. The company also successfully performed the first-in-human ventricular ablation guided by real-time iCMR at Amsterdam University Medical Centre and commenced the VISABL-VT clinical trial. Financially, the company maintained a cash balance of US$50.3 million despite a temporary dip in cash receipts due to non-revenue generating clinical trial enrollments. Imricor’s European sales team expansion and ongoing regulatory advancements are expected to accelerate hospital adoption and commercial launches in Europe and the United States.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.